Dicerna Pharmaceuticals, Inc.
(NASDAQ : DRNA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -1.06%54.950.9%$2397.87m
JNJJohnson & Johnson -0.57%167.800.7%$1089.30m
MRKMerck & Co., Inc. 0.06%81.370.7%$940.61m
ABBVAbbVie, Inc. 1.78%135.891.9%$939.60m
BMYBristol-Myers Squibb Co. 0.54%64.951.0%$741.14m
LLYEli Lilly & Co. -2.21%244.151.1%$712.40m
AZNAstraZeneca Plc 1.29%58.851.0%$246.03m
NVSNovartis AG -0.07%90.560.2%$233.61m
NVONovo Nordisk A/S -3.23%96.340.1%$179.86m
VTRSViatris, Inc. 1.33%15.220.0%$154.37m
GSKGlaxoSmithKline Plc 0.91%45.470.2%$152.85m
RGENRepligen Corp. 0.89%193.266.7%$96.26m
IMMXImmix Biopharma, Inc. 0.17%5.840.0%$89.38m
ALLKAllakos, Inc. -2.68%7.640.0%$85.22m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.60%122.000.0%$79.45m

Company Profile

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.